Comparison of visual acuity outcomes in predominantly classic vs occult lesions in age-related macular degeneration treated with photodynamic therapy

Eye

Volumn 22, Issue 2, 2008, Pages 194-199

  Potter, M J ^a   Szabo, S M ^a   Li, W W ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; DIABETIC RETINOPATHY; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PHOTODYNAMIC THERAPY; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; SCORING SYSTEM; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ACUITY;

EID: 39449131692     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/sj.eye.6702547     Document Type: Article

References (10)

1. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. One-year results of 2 randomized clinical trails - TAP Report 1. Arch Ophthalmol 1999; 117: 1329-1345.
2. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Two year results of 2 randomized clinical trials - TAP Report 2. Arch Ophthalmol 2001; 119: 198-207.
3. Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: Two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001; 131: 541-560.
4. Verteporfin Roundtable Participants. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: Update. Retina 2005; 25: 119-134.
5. Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR, VEGF Inhibition-Study in Ocular Neovascularization Clinical Trial Group Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805-2816.
6. Verteporfin Roundtable 2000 Participapts, TAP Study Group Principle Investigators, VIP Study Group Principal Investigators. Guidelines for using verteporfin (Visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina 2002; 22: 6-18.
7. Ferris III FL, Bailey I. Standardizing the measurement of visual acuity for clinical research studies. Guidelines from the Eye Care Technology Forum. Ophthalmology 1996; 103: 181-182.
8. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10: 407-415.
9. Gould AL. A new approach to the analysis of clinical drug trials with withdrawals. Biometrics 1980; 36: 721-727.
10. Kaiser RS, Berger JW, Williams GA, Tolentino MJ, Maguire AM, Alexander J et al. Variability in fluorescein angiography interpretation for photodynamic therapy in age-related macular degeneration. Retina 2002; 22: 683-690.